Fosgonimeton

Summary

Fosgonimeton (CHEMBL5095419) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including alzheimer disease and lewy body dementia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 5
• Chemistry: 584.6 Da · C27H45N4O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095419
Name	Fosgonimeton
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	156596375
Molecular formula	C27H45N4O8P
Molecular weight	584.6
InChIKey	MBYDCPOKVKDSFD-JTJYXVOQSA-N

SMILES: CCCCCC(=O)N[C@@H](CC1=CC=C(C=C1)OP(=O)(O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(=O)N

IUPAC name: [4-[(2S)-3-[[(2S,3S)-1-[(6-amino-6-oxohexyl)amino]-3-methyl-1-oxopentan-2-yl]amino]-2-(hexanoylamino)-3-oxopropyl]phenyl] dihydrogen phosphate

Also known as: ATH-1017, ATH-1017 FREE ACID, Fosgonimeton, NDX-1017, NDX-1017 FREE ACID, FOSGONIMETON

Parent form; salt/anhydrous children: CHEMBL5095213

Patent coverage: 31 distinct patent families (77 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
Lewy body dementia	1	MONDO:0007488	EFO:0006792
dementia	1	MONDO:0001627	HP:0000726
Parkinson disease	1	MONDO:0005180	MONDO:0005180

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2/PHASE3	2
PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04488419	PHASE2/PHASE3	COMPLETED	ATH-1017 for Treatment of Mild to Moderate Alzheimer’s Disease
NCT04886063	PHASE2/PHASE3	TERMINATED	Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer’s Disease
NCT04491006	PHASE2	COMPLETED	A Study of ATH-1017 in Mild to Moderate Alzheimer’s Disease
NCT04831281	PHASE2	TERMINATED	ATH-1017 Treatment in Subjects With Parkinson’s Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
NCT03298672	PHASE1	COMPLETED	Safety, Tolerability, and Pharmacokinetics Study of NDX-1017

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).